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Abstract
Background: Quality of life may be affected by daily injections of supportive hematopoietic
growth factor medication, which is frequently required by patients with cancer undergoing
chemotherapy. The objective of the study was to identify areas where long-acting derivatives of
current proteins, which require less frequent administration, may provide advantages over existing
therapies that require more frequent administration.
Methods: An observational study was conducted to assess the impact of daily injections of
Filgrastim (Neupogen®; Amgen Inc.) on patients' quality of life. A Subject Outcome Questionnaire
was administered to patients after chemotherapy on 2 consecutive cycles. Time spent for
treatment and patient attitude towards injection frequency were measured. The effect on patients'
daily activities, including their ability to work, was analyzed.
Results: Thirty patients completed the first, and 24 the second, administration of the
Questionnaire across 3 participating sites in the United States. The average patient time
commitment for each daily injection was 78 minutes. Forty-five percent of patients were
moderately to extremely bothered by travel during the first chemotherapy cycle, which increased
to 59% during the second cycle. Forty-four percent and 18% of patients reported having to
rearrange their daily schedules and take time off from work to accommodate each injection at least
some of the time, respectively. Eighty-nine percent of the patients reported a preference for a
longer-acting drug that required fewer injections.
Conclusion: Results indicate that frequent injections represent a significant burden on patients'
lives and that the majority would prefer longer-acting medications that require less frequent
administration and potentially fewer clinic visits.
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When people are diagnosed with cancer, their daily rou-
tines, and those of their caregivers, change dramatically in
order to accommodate chemotherapy treatment. Given
the potential outcome of the disease, patients are often
willing to make significant adjustments in their lives to
integrate the numerous demands of their disease treat-
ment plans. Understandably, this new identity as a "can-
cer patient" may take priority over all other roles when
such sacrifice is believed to be necessary to improve the
probability of a successful outcome. Thus, for patients and
their caregivers, frequent trips to the clinic that necessitate
rearranging schedules, taking time off from work, arrang-
ing for childcare, and missing social and family activities
become an unfortunate part of their daily routines. Many
trips to the clinic may only be for a single injection of sup-
portive therapy. Although injections may seem like simple
and quick procedures, in reality patients frequently
expend a great deal of time and effort each day to receive
them. Meanwhile, the very activities that made life full
and meaningful before their diagnosis have the potential
to be pushed aside for several hours at a time, as patients
receive their treatment. Furthermore, balancing these
activities may become stressful for patients and their car-
egivers. It may also become increasingly more difficult for
patients to carry on with normal life if they are constantly
in the clinic. Therefore, for these patients, a medication
that requires less frequent administration, and offers the
potential of fewer clinic visits and greater flexibility, could
provide a tremendous emotional and physical advantage
over existing therapies.
Although the clinical value of supportive medications
such as Filgrastim (Neupogen®) and Epoetin alfa (PRO-
CRIT®) for the management of chemotherapy-induced
neutropenia (CIN) and anemia (CIA), respectively, is
widely accepted [1–5], the challenges associated with fre-
quent injections that patients encounter have not been
adequately addressed. Several randomized, phase 3 stud-
ies have demonstrated the safety and efficacy of Filgrastim
in the setting of CIN [1,2,6,7]. In these studies, daily Fil-
grastim was administered until an absolute neutrophil
count ≥ 10 × 109/L was documented, resulting in an aver-
age of 10 to 11 injections per chemotherapy cycle.
Although Epoetin alfa is administered less frequently than
Filgrastim, patients may also require frequent injections,
at least once weekly. These injections may further disrupt
the lives of patients, in particular those who may be
required to travel to clinic for their injections.
Recently, 2 novel long-acting supportive care proteins
were approved by the United States (US) Food and Drug
Administration (FDA) for use by patients receiving chem-
otherapy. Pegfilgrastim (Neulasta®) is used to reduce the
incidence of infection, as manifested by febrile neutrope-
nia, in patients with nonmyeloid malignancies receiving
chemotherapy, and darbepoetin alfa (Aranesp®) is used
for the treatment of CIA in patients with nonmyeloid
malignancies. Due to the longer serum half-lives, both
molecules require less frequent administration than prior
treatments. Pegfilgrastim is administered once per chem-
otherapy cycle compared with daily injections of Filgras-
tim, whereas darbepoetin alfa is administered weekly
compared with three times weekly injections of Epoetin
alfa, per the product labeling for each drug. However, in
the US, Epoetin alfa is commonly administered weekly in
the oncology setting [5]; similarly, a less frequent sched-
ule (once every two weeks) for darbepoetin alfa adminis-
tration has been routinely adopted [8].
This study was designed to investigate the burden associ-
ated with frequent injections on patients requiring Filgras-
tim therapy. The results from this study can be used to
identify areas in a patient's treatment where long-acting
agents could provide advantages over existing therapies
that require more frequent administration.
Methods
Study population
Oncology patients in participating ambulatory oncology
clinics who were expected to receive at least 2 cycles of Fil-
grastim therapy were eligible for this study; those who
were unable to understand spoken English at a 6th grade
level or with severe comorbidities were excluded. Patients
who met these eligibility criteria were then randomly
selected and contacted for their interest in participating in
the study.
The study protocol was approved by the Institutional
Review Board at each of the 3 investigative sites, and writ-
ten informed consent was obtained from each study par-
ticipant before the protocol was initiated.
Study design
This observational study was designed to assess the
impact of frequent injections on the disruption of daily
activities, time commitment, physical discomfort, and sat-
isfaction with treatment in patients receiving chemother-
apy who require supportive therapy. Study participants
provided answers to a self-administered Subject Outcome
Questionnaire (SOQ) completed 15 ± 3 days after chem-
otherapy on 2 consecutive chemotherapy cycles. The SOQ
(see additional file 1: Subject outcome questionnaire) was
developed to assess the burden associated with daily injec-
tions on patients receiving Filgrastim post-chemotherapy.
The items included in the questionnaire were based on
results of 2 focus group studies of cancer patients who
received Filgrastim during their chemotherapy treatment
(data not published). Although the sample sizes of these
exploratory studies were small (9 in one and 6 in thePage 2 of 6
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groups were the disruption in daily activities by, and time
spent on, receiving daily injections of Filgrastim (up to 14
daily injections per cycle). This SOQ represents the first
systematic and quantitative survey of the burden of fre-
quent injections of hematopoietic growth factor on
patients receiving chemotherapy. The SOQ has not been
validated, and formal studies are underway to assess its
validity and reliability and to examine the relationship
between the SOQ and several cancer-specific health-
related quality of life instruments.
The extent of disruption of daily activities was measured
in terms of time spent travelling to and from the clinic.
Patient concerns and attitudes toward frequent injections
were assessed on a self-rating scale of 1 to 5, with 1 repre-
senting the least amount of disruption, interference or
time commitment, and 5 the greatest amount of disrup-
tion, interference or time commitment. Patients also rated
the extent of physical discomfort associated with injection
on a self-rating scale of 0 to 10, with 0 representing no dis-
comfort and 10 representing extreme discomfort. Also
assessed were patient satisfaction with Filgrastim treat-
ment (based on a 1 to 5 scale, with 1 corresponding to not
at all satisfied and 5 corresponding to very much satisfied)
and preference for a longer-acting drug. Selected patient
responses were grouped into various categories for presen-
tation of data. The use of various scales was intended to
provide insight into the degree of effect of treatment on
patients' lives. However, responses were neither weighted
nor compared with each other, and a total score was not
calculated. Participating study sites were the Cancer
Center of Albany Medical Center, Northern Indiana Can-
cer Research Consortium (NICRC), and University of Cal-
ifornia Los Angeles (UCLA) in the United States.
Statistical methods
Analysis was performed only on completed question-
naires; no imputation of data was made. Descriptive sta-
tistics were performed for each question on the SOQ.
Items were analyzed by site and chemotherapy cycle (first
or second). Results from both chemotherapy cycles and
from all 3 sites were combined for the analyses. Means
and standard deviations (SD) were calculated for contin-
uous responses, and frequencies were calculated for cate-
gorical responses. The statistical association between the
demographic characteristics listed in Table 1 and patient
responses listed in Table 2 was calculated using the chi-
square test.
Results
Thirty patients completed the first administration of the
SOQ across all 3 sites (6 patients at Cancer Center of
Albany Medical Center; 7 at NICRC; and 17 at UCLA).
Twenty-four patients completed the second administra-
tion of the SOQ. Demographic characteristics were similar
among the study centers and are provided in Table 1. The
average age of participants was approximately 61 years
(range, 21 to 80 years) and 70% were female, reflecting
the fact that most of the patients at the study sites were
older women with breast cancer. Nearly half of the
patients reported college level education or above; 45% of
participants had Medicare insurance and/or annual
household income greater than $50,000. Approximately
one quarter of the enrolled participants were employed in
some capacity.
Patients received injections ranging in frequency from 1 to
15 per chemotherapy cycle. The effect of daily Filgrastim
injections on quality-of-life issues is shown in Table 2.
The mean (SD) time commitment for daily Filgrastim
treatment was 78 (72) minutes, including 60 (48) min-
utes on travel to and from the clinic and 18 (24) minutes
waiting at the clinic per visit. Most patients (60%) drove
themselves to the clinic for their injection, while 40%
were accompanied by a friend or relative. Forty-five per-
cent of patients were moderately to extremely bothered by
travel during chemotherapy cycle 1 (≥3 on the 5-point
scale); this percentage increased to 59% during the subse-
quent cycle.
Forty-four percent of patients reported that the frequency
of Filgrastim injections interfered with their daily activi-
ties at least some to all of the time (≥3 on the 5-point
Table 1: Demographic characteristics of study population
Age, years
mean (SD) 60.8 (13.9)
range 21–80
≥ 65 (%) 45%
Sex, female (%) 70%
Level of education, college degree or higher 47%
Insurance coverage by Medicare 45%
Annual household income, >$50,000/year 45%
Part time or full time employment 26%Page 3 of 6
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range their schedules for medical visits at least some to all
of the time. Eighteen percent of working patients took
time off from work for injections at least some to all of the
time.
The associations between demographic characteristics
(Table 1) and selected patient responses to the SOQ
(Table 2) were analyzed retrospectively. Younger patients
(< 65), compared with older (≥ 65) patients, were more
likely to take time off from work (31% vs 4%, respectively;
[p < 0.01]) for Filgrastim administration. In addition,
although statistical significance was not achieved, a simi-
lar trend was observed wherein younger patients were
more likely than older patients to miss appointments
(18.5% vs 8%, respectively; [p = 0.13]) for Filgrastim
administration. Finally, a higher percentage of younger
patients, compared with older patients, reported that they
would have used the time that was spent travelling to and
from the clinic to work for pay (36% vs 16%, respectively;
[p < 0.05]). Apart from age, no significant associations
were found between the other demographic characteris-
tics (eg, gender, level of education, insurance coverage,
annual household income, employment) and selected
patient responses to the SOQ.
Physical discomfort was the least burdensome to patients
when compared with the other variables measured. The
majority of patients reported little to no discomfort due to
injections. The mean (SD) physical discomfort score asso-
ciated with the injection was 2.1 (2.5) on a 0 to 10 scale.
Over 90% of the patients were "moderately" to "very
much" satisfied with Filgrastim therapy. However, 89% of
the patients who had received daily Filgrastim injections
reported that they would prefer a longer-acting drug that
required fewer injections.
Discussion
This study was conducted in oncology patients receiving
chemotherapy and Filgrastim. The study assessed the
impact of frequent Filgrastim injections on the quality of
life of patients receiving chemotherapy and, in particular,
the challenges associated with frequent clinic visits.
Results from this study indicate that the majority (89%) of
patients who had received daily Filgrastim injections
would prefer a longer-acting therapy that required fewer
injections, and thus fewer trips to the clinic. A wide variety
of burdens on patient quality of life due to injections were
identified in the study. In particular, the frequency of
appointments and travelling to and from the clinic were
the 2 most common disruptions, as reported by greater
than 70% of the patients.
As patients' lives are disrupted by cancer therapy, treat-
ments that allow a more normal daily routine could
improve their quality of life. Patients, as well as their car-
egivers, could benefit from treatments that achieve opti-
mal outcomes with the least amount of intrusion into
their lives. Pegfilgrastim has recently been approved by
the FDA for the prevention of neutropenia induced by
chemotherapy, and has been shown in clinical studies to
be comparable to Filgrastim in efficacy and safety. How-
ever, unlike Filgrastim, which requires daily injections
when prescribed as needed, longer-acting pegfilgrastim is
administered only once per chemotherapy cycle. In our
study, patients reported an average time commitment of
1.3 hours per injection visit. Furthermore, two fifths of the
patients were accompanied to the clinic by a relative or
friend; however, the time spent by a caregiver per injection
visit was not determined. Thus, the total time commit-
ment would likely be greater if caregiver time per visit had
also been reported. The possibility of saving time on
injections in order to attend to other activities of daily life
would be of obvious appeal not only to patients, but to
caregivers as well.
Table 2: Summary of selected patient responses to the SOQ
Effect of treatment on time commitment
Mean (SD) travel time to/from the clinic 60 (48) minutes per visit
Mean (SD) waiting time at the clinic 18 (24) minutes per visit
Effect of treatment on patient attitude
Attitude towards travel for treatment during first chemotherapy cycle Moderately to extremely bothered, 45%
Attitude towards travel for treatment during second chemotherapy cycle Moderately to extremely bothered, 59%
Disruption of daily activities caused by injection frequency Reported disruption some to all of the time, 44%
Disruption of work schedule caused by injection frequency Took time off from work for treatment some to all of the time, 18%
Effect of treatment on patient satisfaction and drug preference
Experience with Filgrastim therapy after most recent chemotherapy cycle Moderately to very much satisfied, > 90%
Choice between daily injections versus newer, longer-acting drug Preference for new drug, 89%Page 4 of 6
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olated to other medications that also require frequent
administration. Darbepoetin alfa, a recently approved
erythropoietic agent, can be administered less frequently
than Epoetin alfa due to its approximately 3-fold longer
half-life. Currently, patients receiving chemotherapy
require 1 to 3 injections of Epoetin alfa a week [5], while
in clinical studies, darbepoetin alfa was effective when
injected as infrequently as every 2, 3, or 4 weeks [8–12].
Both pegfilgrastim and darbepoetin alfa represent a treat-
ment advance in supportive care in oncology by providing
patients the benefits of less frequent injections.
This study may have underestimated the real burden of
frequent injections to the broader cancer patient popula-
tion, since the study participants were, on average, older
(61 years) and only a quarter of them were employed. A
younger patient population may have experienced consid-
erably more inconvenience caused by frequent trips to the
clinic since a greater percentage of these patients would be
potentially working, caring for children, and involved in a
great number of personal and family activities that require
their participation. As was observed in this study, younger
patients were more likely than older patients to take time
off from work for Filgrastim treatment. Other demo-
graphic factors may be associated with patient responses;
however, they were not found in this study, possibly due
to the small sample size. Another potential limitation of
the study is that the time spent by caregivers in assisting
patients was not collected, which could also contribute to
an underestimation of the burden of frequent injections.
Finally, it has been suggested previously that the need to
make multiple visits increases the risk of missing required
injections, as reported in the setting of administering vac-
cinations [13]. The effect of frequency of oral medications
on treatment compliance has been demonstrated for anti-
hypertensive medications with patients showing higher
compliance with simpler regimens [14]. The potential
impact of fewer injections on a patient's ability to comply
with complete Filgrastim therapy and other treatment for
their disease would be of further interest.
Conclusions
Although the SOQ remains to be validated, the results
from this study indicate that travelling to the clinic to
receive frequent injections of supportive care medications
is a burden to patients with cancer and negatively affects
their quality of life. Although current treatments are clini-
cally adequate, new long-acting therapeutics have the
potential to improve significantly the quality of patients'
lives by requiring fewer injections. Patients should be
made aware of these newer alternatives which may help to
decrease the burden of treatment in their lives. A control-
led trial comparing these newer agents with current treat-
ments would help to more accurately identify the impact
of frequent injections in patients receiving chemotherapy.
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